IDEAYA Biosciences, Inc. (IDYA)
IDYA Stock Price Chart
Explore IDEAYA Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze IDYA price movements and trends.
IDYA Company Profile
Discover essential business fundamentals and corporate details for IDEAYA Biosciences, Inc. (IDYA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 May 2019
Employees
131.00
Website
https://www.ideayabio.comCEO
Yujiro S. Hata
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IDYA Financial Timeline
Browse a chronological timeline of IDEAYA Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 11 Feb 2026
Upcoming earnings on 3 Nov 2025
EPS estimate is -$0.12, while revenue estimate is $63.52M.
Earnings released on 5 Aug 2025
EPS came in at -$0.88 falling short of the estimated -$0.85 by -3.53%.
Earnings released on 6 May 2025
EPS came in at -$0.82 falling short of the estimated -$0.75 by -9.33%.
Earnings released on 13 Feb 2025
EPS came in at -$1.49 falling short of the estimated -$0.67 by -122.39%, while revenue for the quarter reached $7.00M , beating expectations by +180.56%.
Earnings released on 4 Nov 2024
EPS came in at -$0.60 surpassing the estimated -$0.67 by +10.45%.
Earnings released on 6 Aug 2024
EPS came in at -$0.68 falling short of the estimated -$0.55 by -23.64%.
Earnings released on 7 May 2024
EPS came in at -$0.53 matching the estimated -$0.53.
Earnings released on 20 Feb 2024
EPS came in at -$0.52 falling short of the estimated -$0.49 by -6.12%, while revenue for the quarter reached $3.92M , missing expectations by -55.64%.
Earnings released on 7 Nov 2023
EPS came in at -$0.46 surpassing the estimated -$0.47 by +2.13%, while revenue for the quarter reached $8.04M , beating expectations by +2.53%.
Earnings released on 10 Aug 2023
EPS came in at -$0.50 surpassing the estimated -$0.53 by +5.66%, while revenue for the quarter reached $3.54M , missing expectations by -21.42%.
Earnings released on 9 May 2023
EPS came in at -$0.49 surpassing the estimated -$0.51 by +3.92%, while revenue for the quarter reached $7.88M , beating expectations by +64.51%.
Earnings released on 7 Mar 2023
EPS came in at -$0.50 surpassing the estimated -$0.57 by +12.28%, while revenue for the quarter reached $4.02M , missing expectations by -42.54%.
Earnings released on 8 Nov 2022
EPS came in at $0.04 surpassing the estimated -$0.65 by +106.15%, while revenue for the quarter reached $29.70M , beating expectations by +347.15%.
Earnings released on 15 Aug 2022
EPS came in at -$0.57 matching the estimated -$0.57, while revenue for the quarter reached $5.85M , missing expectations by -23.95%.
Earnings released on 10 May 2022
EPS came in at -$0.36 surpassing the estimated -$0.41 by +12.20%, while revenue for the quarter reached $11.36M , beating expectations by +69.31%.
Earnings released on 15 Mar 2022
EPS came in at -$0.47 falling short of the estimated -$0.31 by -51.61%, while revenue for the quarter reached $2.96M , missing expectations by -67.00%.
Earnings released on 15 Nov 2021
EPS came in at -$0.31 falling short of the estimated -$0.29 by -6.90%, while revenue for the quarter reached $8.98M , missing expectations by -0.04%.
Earnings released on 10 Aug 2021
EPS came in at -$0.33 falling short of the estimated -$0.07 by -371.43%, while revenue for the quarter reached $8.76M , meeting expectations.
Earnings released on 10 May 2021
EPS came in at -$0.28 matching the estimated -$0.28, while revenue for the quarter reached $7.25M , beating expectations by +3.85%.
Earnings released on 23 Mar 2021
EPS came in at -$0.18 matching the estimated -$0.18, while revenue for the quarter reached $10.57M .
Earnings released on 12 Nov 2020
EPS came in at -$0.17 falling short of the estimated $1.34 by -112.69%, while revenue for the quarter reached $8.97M , missing expectations by -48.33%.
IDYA Stock Performance
Access detailed IDYA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.